domenica 8 luglio 2018

# pharma: an ethno-drug revisited ... Ayahuasca, prelude of a "magic string" in neuropharmacology

To [AA] << knowledge, this is the first controlled trial to test a psychedelic substance in treatment-resistant depression. Overall, this study brings new evidence supporting the safety and therapeutic value of ayahuasca, dosed within an appropriate setting, to help treat depression. >>

Palhano-Fontes F, Barreto D, et al.  Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2018 Jun 15:1-9. doi: 10.1017/S0033291718001356.

<< Ayahuasca is a mixture of herbs, traditionally used for spiritual and therapeutic purposes. The main active ingredients are N,N-DMT, a potent psychedelic, and several molecules that inhibit the enzyme MAO. The MAO inhibitors serve to prevent the N,N-DMT from being broken down by the digestive system, allowing it to enter the bloodstream and cause hallucinations and other alterations of consciousness. >>

Ayahuasca, the Psychedelic Antidepressant? Neuroskeptic. June 17, 2018.

John Horgan. Yes, Make Psychedelics Legally Available, but Don't Forget the Risks. SciAm. July 6, 2018.


"magic string"

# pharma: waiting for new 'magic strings': psilocybin to treat depression. Oct 17, 2017.

# s-brain: 70-years after; Dr. Albert revisited. Aug 22, 2016.

# s-pharma-n-ethnomed: psilocybin. Dec 14, 2015.

Nessun commento:

Posta un commento